Sökning: "venetoclax"
Hittade 5 avhandlingar innehållade ordet venetoclax.
1. Improving prognostication and treatment choices for patients with AML
Sammanfattning : The treatment landscape of the aggressive haematological malignancy acute myeloid leukaemia (AML) has expanded but the prognosis is still unsatisfactory poor. Here, we aimed at improving prognostication and treatment choices in AML by addressing current clinical obstacles to successful AML treatment. LÄS MER
2. Identification and Functional Significance of Aberrant Long Non-coding RNAs in Acute Myeloid Leukemia : Biological and Prognostic Implications
Sammanfattning : Acute myeloid leukemia (AML) is the most frequently diagnosed type of acute leukemia in adults. It commonly affects people aged 60 or older, as incidence increases with age, and it is characterized by the accumulation of immature hematopoietic progenitor cells in the bone marrow. LÄS MER
3. Mechanisms of therapy resistance in acute lymphoblastic leukemia
Sammanfattning : Acute lymphoblastic leukemia (ALL) is a highly aggressive pediatric cancer that can affect both B cells and T cells. The advent of new therapies has increased the cure rates for both B-ALL and T-ALL patients. However, some patients still experience relapse with a variable response to the treatment and display poor survival. LÄS MER
4. ROR1 – a druggable target : preclinical studies of ROR1 and combinatorial partners in malignancies
Sammanfattning : Cancer cells are masters of adaption, and their ability to sustain proliferative signaling presents a complicated challenge to cancer treatment. Therefore, novel drugs that attack key drivers of cancer cell growth are urgently needed. LÄS MER
5. Cellular and personalized therapies in multiple myeloma with special emphasis on retargeted natural killer cells
Sammanfattning : Multiple myeloma (MM) is a clonal plasma cell malignancy accounting for approximately 10% of all hematological cancer cases. Despite considerable advances in MM management, which led to exceptional response and survival rates, patients still experience relapse and cure remains elusive. LÄS MER